CD79A and myeloid sarcoma: In the present study, we were able to show changes in the diagnostic CSF biomarkers in the form of a lower frequency of an intrathecal fraction of FLCk in MS patients with a progressive disease course, as well as changes in the humoral immune profile in the form of higher local IgA concentrations in patients with progressive MS.